CUREVAC NV (5CV.DE) Stock Price & Overview
FRA:5CV • NL0015436031
Current stock price
The current stock price of 5CV.DE is 3.892 EUR. Today 5CV.DE is up by 0.36%. In the past month the price decreased by -12.97%. In the past year, price decreased by -8.77%.
5CV.DE Key Statistics
- Market Cap
- 876.362M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.71
- Dividend Yield
- N/A
5CV.DE Stock Performance
5CV.DE Stock Chart
5CV.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to 5CV.DE. When comparing the yearly performance of all stocks, 5CV.DE is a bad performer in the overall market: 88.23% of all stocks are doing better.
5CV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE. 5CV.DE has only an average score on both its financial health and profitability.
5CV.DE Earnings
On November 24, 2025 5CV.DE reported an EPS of -0.08 and a revenue of 54.13M. The company beat EPS expectations (30.28% surprise) and beat revenue expectations (396.01% surprise).
5CV.DE Forecast & Estimates
11 analysts have analysed 5CV.DE and the average price target is 4.02 EUR. This implies a price increase of 3.22% is expected in the next year compared to the current price of 3.892.
For the next year, analysts expect an EPS growth of -163.99% and a revenue growth -84.14% for 5CV.DE
5CV.DE Groups
Sector & Classification
5CV.DE Financial Highlights
Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -247.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 182.11% | ||
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.03 |
5CV.DE Ownership
5CV.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 31.06 | 44.565B | ||
| ARGX | ARGENX SE | 30.62 | 44.006B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.431B | ||
| 2X1 | ABIVAX SA | N/A | 8.246B | ||
| ABVX | ABIVAX SA | N/A | 7.961B | ||
| GLPG | GALAPAGOS NV | N/A | 1.638B | ||
| GXE | GALAPAGOS NV | N/A | 1.612B | ||
| NANO | NANOBIOTIX | N/A | 1.342B | ||
| PHGN | PHARMING GROUP NV | 49.55 | 1.054B | ||
| PHARM | PHARMING GROUP NV | 49.12 | 1.05B | ||
| IVA | INVENTIVA SA | N/A | 1.004B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 996.493M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 991.483M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 5CV.DE
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
IPO: 2020-08-14
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 904
Phone: 49707198830
CUREVAC NV / 5CV.DE FAQ
Can you describe the business of CUREVAC NV?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
What is the current price of 5CV stock?
The current stock price of 5CV.DE is 3.892 EUR. The price increased by 0.36% in the last trading session.
Does CUREVAC NV pay dividends?
5CV.DE does not pay a dividend.
How is the ChartMill rating for CUREVAC NV?
5CV.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is CUREVAC NV (5CV.DE) stock traded?
5CV.DE stock is listed on the Frankfurt Stock Exchange exchange.
Would investing in CUREVAC NV be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 5CV.DE.
Is CUREVAC NV (5CV.DE) expected to grow?
The Revenue of CUREVAC NV (5CV.DE) is expected to decline by -84.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.